A major challenge in the drug discovery field is the appropriate and timely usage of key technologies, methodologies, and cutting-edge tools to qualitatively and quantitatively provide the best benchmark level analysis available.

However, internalization of the literally hundreds of possible analytical disciplines can be cost prohibitive not only to the company offering the services but to the client as well who must encumber the cost that is passed along for carrying such a large and inefficient internal service structure.

In order to achieve the best of both worlds, XTAL formed the key alliances with the following companies:

SBH Sciences
SBH Sciences
is one of the premier cytokine bioassay services resources in the US. In their two comprehensive state-of-the-art cell culture facilities, SBH provides critical pre-clinical process development services. These include insect and mammalian based cell culture, protein purification, (anti) cytokine bioassays, ELISA kits for cytokine & biomarker measurements, recombinant cytokines, monoclonal and polyclonal antibodies to the biopharmaceutical, diagnostics and biotechnology industries.
DNA-SEQ Alliance, Inc.
DNA-SEQ Alliance, Inc.
is committed to reducing the time between emerging science and medical practice by providing oncologists a unique genomic data gathering, analysis and targeting service. DNA-SEQ provides reports to oncologists to more precisely match the patient’s genomic profile with targeted therapies. The report is designed to both enhance the oncologist’s traditional cancer treatment decisions and to dramatically expand the treatment options that can be offered to the patient.
Woodland Biosciences
Woodland Biosciences
is a preclinical contract research organization dedicated to advancing research through the innovative use of cancer cell lines and primary patient tumor samples. They provide complex animal modeling of PK/PD and efficacy studies, leading directly to to primary tumor models designed to improve clinical success.
Beantown BioTech
Beantown BioTech
is a contract drug discovery laboratory offering assays in neurodegenerative, oncology, autoimmune, inflammatory, cardiovascular, metabolic, liver and kidney diseases. Assay platforms include Fluorescence, Luminescence, Absorbance, AlphaScreen, Electrochemiluminescence, SPR, FP, TR-FRET, HTRF and ELISA.
ProCrysta Biologix Inc.
ProCrysta Biologix Inc.
is dedicated to develop and commercialize novel protein therapeutics for the treatment of infectious diseases and metabolic disorders with unmet medical needs. The company’s innovative approach focuses on designing of effective protein therapies and on drug delivery options for oral, subcutaneous, topical and pulmonary routes using its crystallization technology.
pION Inc.
pION Inc.
is the world leader in permeability and solubility measurement. They provide instruments and analytical services for ADME, solubility, permeability, dissolution, pKa and log P determination.

XTAL is proud to be part of the Chemical Biology Consortium (CBC) in the NCI Experimental Therapeutics (NExT) program, which brings together chemical biologists and molecular oncologists from government, industry, and academia to address unmet needs in therapeutic oncology.

Members of the consortium contribute their expertise in high throughput screening, structural biology, medicinal chemistry, compound profiling, cancer cell biology, and animal models for oncology to advance early stage drug discovery projects to the clinical candidate stage. Through the CBC and interactions among participants, the NCI’s drug discovery and development pipeline is active from target identification to proof-of-concept clinical trials.

The CBC operates as a collaborative network of 7 Dedicated Centers and 15 Specialized Centers. The Dedicated Centers support the advancement of NExT discovery projects through all discovery stages and provide scientific leadership for the Consortium. The Specialized Centers provide uniquely focused technologies that facilitate progression of NExT discovery projects through specific discovery stages.